Survey: Biopharma gets a bad grade on gender diversity

John Carroll The biopharma industry doesn't do a very good job when it comes down to the way it handles gender diversity. And if you're a woman in this business, chances are ...

Struggling Eisai gets FDA approval for cancer drug Halaven for liposarcoma

Eric Palmer Japan's Eisai got a much-needed boost on Thursday when the FDA approved its cancer drug, Halaven, for treatment of liposarcoma for patients in which the cancer has advanced ...

Shire gets back on track with once-rejected eye drug

Damian Garde Shire has resubmitted the once-rejected eye treatment lifitegrast for FDA approval, handing in new data the company hopes will get its self-described blockbuster drug onto ...

UPDATED: Shire finally gets it done, bagging Baxalta in $32B buyout

John Carroll It took a few months, but Shire has wrapped a $ 32 billion deal to acquire Baxalta, providing CEO Flemming Ornskov with the big merger that he has been promising investors. FierceBiotech ...

Sanofi gets first approval for long-anticipated vaccine against dengue fever

Eric Palmer After two decades and $ 1.65 billion in research, French drugmaker Sanofi has gotten an approval for the world's first vaccine against the sometimes deadly dengue fever, ...

Takeda gets enough takers to complete $2.3B Actos settlement

Eric Palmer A month ago it appeared like Takeda might not get enough takers to move forward with its sweeping $ 2.3 billion offer to settle thousands of claims over the cancer risks ...

India’s Cipla gets U.S. beachhead with $550M deal for 2 generics operations

Eric Palmer India's Cipla has lagged behind its compatriots in challenging U.S. drugmakers on their own turf, currently getting less than 10% of its revenues from the lucrative ...

Tesaro gets a green light for rolapitant, triggering Merck showdown

John Carroll The FDA has given Tesaro a green light to start marketing rolapitant to help prevent some of the common side effects of chemotherapy. And now Tesaro will wage a David-vs.-Goliath ...

Lilly’s CEO keeps faith in the pipeline as biotech gets ‘too expensive’

Damian Garde Eli Lilly is staking its future on a pair of high-stakes Phase III programs, shying away from any big biotech buyouts as sticker prices continue to soar. FierceBiotech ...

Post-Sarepta, Art Krieg gets $20M to take a shot at an immuno-oncology Checkmate

John Carroll A year after getting bounced from a turbulent Sarepta, Art Krieg is prepping for his next act in biotech, snatching a failed lead immunology drug from the dying, Zurich-based ...

Biogen gets beaten up as slowing Tecfidera sales lead it to trim forecast

Eric Palmer The speed bump that sales of Biogen's Tecfidera hit earlier this year, slowing its growth, has turned into a big old pothole and it has shaken investors pretty hard ...

Bristol-Myers’ next-gen HIV med gets FDA ‘breakthrough’ designation

Tracy Staton Bristol-Myers Squibb nabbed a "breakthrough" tag from the FDA for its next-gen HIV therapy aimed at patients who become resistant to the drugs now in use. FiercePharma ...
Page 1 of 812345...Last »
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS